| __timestamp | Blueprint Medicines Corporation | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 31844000 | 189101000 |
| Thursday, January 1, 2015 | 48588000 | 96351000 |
| Friday, January 1, 2016 | 81131000 | 95967000 |
| Sunday, January 1, 2017 | 144687000 | 112171000 |
| Monday, January 1, 2018 | 243621000 | 182257000 |
| Tuesday, January 1, 2019 | 331450000 | 336964000 |
| Wednesday, January 1, 2020 | 326860000 | 547851000 |
| Friday, January 1, 2021 | 601033000 | 693716000 |
| Saturday, January 1, 2022 | 477419000 | 891813000 |
| Sunday, January 1, 2023 | 427720000 | 1044071000 |
| Monday, January 1, 2024 | 341433000 | 910408000 |
Cracking the code
In the competitive world of biotechnology, innovation is key. Over the past decade, Exelixis, Inc. and Blueprint Medicines Corporation have been at the forefront of this race, investing heavily in research and development (R&D). From 2014 to 2023, Exelixis consistently outpaced Blueprint Medicines in R&D spending, with a notable peak in 2023 where Exelixis invested nearly 2.5 times more than Blueprint. This trend highlights Exelixis's commitment to innovation, as their R&D expenses grew by over 450% from 2014 to 2023. Meanwhile, Blueprint Medicines also showed a strong upward trajectory, increasing their R&D investment by approximately 1,240% over the same period. These investments underscore the companies' dedication to pioneering new treatments and therapies, setting the stage for future breakthroughs in the biotech industry.
R&D Spending Showdown: Gilead Sciences, Inc. vs Blueprint Medicines Corporation
Who Prioritizes Innovation? R&D Spending Compared for Dr. Reddy's Laboratories Limited and Blueprint Medicines Corporation
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Exelixis, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Research and Development Investment: Exelixis, Inc. vs Alkermes plc
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Blueprint Medicines Corporation or Grifols, S.A.: Who Invests More in Innovation?
Blueprint Medicines Corporation vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending
Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Blueprint Medicines Corporation and Mesoblast Limited
Research and Development Investment: Blueprint Medicines Corporation vs Viridian Therapeutics, Inc.